HDAC6 as privileged target in drug discovery: A perspective
Abstract HDAC6, a class IIB HDAC isoenzyme, stands unique in its structural and
physiological functions. Besides histone modification, largely due to its cytoplasmic …
physiological functions. Besides histone modification, largely due to its cytoplasmic …
Ibrutinib resistance mechanisms and treatment strategies for B-cell lymphomas
B George, S Mullick Chowdhury, A Hart, A Sircar… - Cancers, 2020 - mdpi.com
Chronic activation of B-cell receptor (BCR) signaling via Bruton tyrosine kinase (BTK) is
largely considered to be one of the primary mechanisms driving disease progression in B …
largely considered to be one of the primary mechanisms driving disease progression in B …
Novel agents in chronic lymphocytic leukemia: new combination therapies and strategies to overcome resistance
M Fürstenau, B Eichhorst - Cancers, 2021 - mdpi.com
Simple Summary Nowadays, many patients with chronic lymphocytic leukemia (CLL) are
treated with so-called novel agents, including BTK inhibitors, Bcl-2 inhibitors and PI3K …
treated with so-called novel agents, including BTK inhibitors, Bcl-2 inhibitors and PI3K …
In silico design of novel benzohydroxamate-based compounds as inhibitors of histone deacetylase 6 based on 3D-QSAR, molecular docking, and molecular dynamics …
H Chu, Q He, J Wang, Y Hu, Y Wang, Z Lin - New Journal of Chemistry, 2020 - pubs.rsc.org
Histone deacetylase 6 (HDAC6) can deacetylate many substrates, including α-tubulin,
cortactin, and HSP90α. This makes HDAC6 an interesting, emerging target. In this study, we …
cortactin, and HSP90α. This makes HDAC6 an interesting, emerging target. In this study, we …
Unique molecular interaction with the histone deacetylase 6 catalytic tunnel: crystallographic and biological characterization of a model chemotype
Histone deacetylase 6 (HDAC6) is involved in multiple regulatory processes, ranging from
cellular stress to intracellular transport. Inhibition of aberrant HDAC6 activity in several …
cellular stress to intracellular transport. Inhibition of aberrant HDAC6 activity in several …
HDAC6 inhibition alleviates CLL-induced T-cell dysfunction and enhances immune checkpoint blockade efficacy in the Eμ-TCL1 model
Development of chronic lymphocytic leukemia (CLL) is associated with severe immune
dysfunction. T-cell exhaustion, immune checkpoint upregulation, and increase of regulatory …
dysfunction. T-cell exhaustion, immune checkpoint upregulation, and increase of regulatory …
HDAC6—an emerging target against chronic myeloid leukemia?
Imatinib became the standard treatment for chronic myeloid leukemia (CML) about 20 years
ago, which was a major breakthrough in stabilizing the pathology and improving the quality …
ago, which was a major breakthrough in stabilizing the pathology and improving the quality …
Oncogenic role and target properties of the lysine-specific demethylase KDM1A in chronic lymphocytic leukemia
Q Jiang, J Stachelscheid, J Bloehdorn… - Blood, The Journal …, 2023 - ashpublications.org
In chronic lymphocytic leukemia (CLL), epigenetic alterations are considered to centrally
shape the transcriptional signatures that drive disease evolution and underlie its biological …
shape the transcriptional signatures that drive disease evolution and underlie its biological …
RPPA-based proteomics recognizes distinct epigenetic signatures in chronic lymphocytic leukemia with clinical consequences
AD van Dijk, TL Griffen, YH Qiu, FW Hoff, E Toro… - Leukemia, 2022 - nature.com
The chronic lymphocytic leukemia (CLL) armamentarium has evolved significantly, with
novel therapies that inhibit Bruton Tyrosine Kinase, PI3K delta and/or the BCL2 protein …
novel therapies that inhibit Bruton Tyrosine Kinase, PI3K delta and/or the BCL2 protein …
Rational cotargeting of HDAC6 and BET proteins yields synergistic antimyeloma activity
JS Carew, CM Espitia, W Zhao, V Visconte… - Blood …, 2019 - ashpublications.org
Inhibition of bromodomain and extra terminal (BET) protein family members, including
BRD4, decreases the expression of c-MYC and other key oncogenic factors and also …
BRD4, decreases the expression of c-MYC and other key oncogenic factors and also …